Posting this after reading this from prohealth board, http://www.prohealth.com/me-cfs/library/showarticle.cfm?libid=17047 Suvorexant (MK-4305) is an orexin receptor antagonist in development by Merck & Co. The drug works by turning off wakefulness rather than by inducing sleep. This drug for sleep disorders has completed three Phase III trials and is one of several such compounds currently in development, the others being Actelion's ACT-078573 and GlaxoSmithKline's SB-649,868 Sounds interesting, i wonder how much this will cost when it first comes out. cheers!!!